Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- LYS.PA
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Lysogene SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology & Medical Research
- Market cap
- 4.95M
- Ent value
- 15.42M
- Price/Sales
- 0.41
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -2.32%
- 1 year return
- -63.51%
- 3 year return
- -53.67%
- 5 year return
- -32.60%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
LYS.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.41 |
| Price to Book | - |
| EV to Sales | 1.27 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 17.70M |
| EPS (TTM) | -0.73 |
| FCF per share (TTM) | -0.82 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 12.17M |
| Gross profit (TTM) | -5.08M |
| Operating income (TTM) | -12.39M |
| Net income (TTM) | -12.91M |
| EPS (TTM) | -0.73 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -41.75% |
| Operating margin (TTM) | -101.77% |
| Profit margin (TTM) | -106.05% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.72M |
| Net receivables | 983.00K |
| Total current assets | 13.24M |
| Goodwill | 0.00 |
| Intangible assets | 272.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 15.34M |
| Accounts payable | 374.00K |
| Short/Current long term debt | 12.48M |
| Total current liabilities | 6.20M |
| Total liabilities | 18.20M |
| Shareholder's equity | -2.86M |
| Net tangible assets | -3.13M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -14.37M |
| Capital expenditures (TTM) | 286.00K |
| Free cash flow (TTM) | -14.66M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -84.14% |
| Return on Invested Capital | -147.53% |
| Cash Return on Invested Capital | -167.54% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| LYS.PA | S&P500 | |
| Current price drop from All-time high | -95.90% | -8.20% |
| Highest price drop | -96.60% | -56.47% |
| Date of highest drop | 23 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -64.92% | -11.07% |
| Avg time to new high | 1610 days | 12 days |
| Max time to new high | 1609 days | 1805 days |
COMPANY DETAILS
Marketcap
4.95M
Marketcap category
Small-cap
Description
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a research collaboration with the Yeda Research and Development Co Ltd. for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was founded in 2009 and is based in Neuilly-sur-Seine, France.
Employees
22
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found